Skip to main content

  • FDA expands MitraClip indication to include patients with secondary mitral regurgitation

    FDA expands MitraClip indication to patients with secondary mitral regurgitation

  • FDA expands MitraClip indication to include patients with secondary mitral regurgitation

    The U.S. Food and Drug Administration (FDA) approved a new indication for MitraClip (Abbott Vascular) on Thursday, several months after COAPT trial results showed that the device plus optimal medical therapy was a significantly more effective treatment for patients with heart failure (HF) and moderate to severe secondary mitral regurgitation (MR) than optimal medical therapy alone was.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details